Get the Stockscreener App
108.62
2.46%
-2.74
Incyte Corp stock is traded at $108.62, with a volume of 2.60M.
It is down -2.46% in the last 24 hours and down -10.58% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
See More
Previous Close:
$111.36
Open:
$111.29
24h Volume:
2.60M
Relative Volume:
1.37
Market Cap:
$22.02B
Revenue:
$5.36B
Net Income/Loss:
$1.43B
P/E Ratio:
15.36
EPS:
7.0718
Net Cash Flow:
$1.42B
1W Performance:
-3.65%
1M Performance:
-10.58%
6M Performance:
+13.68%
1Y Performance:
+28.20%
1-Day Range:
$107.78
$111.67
1-Week Range:
$107.78
$115.49
52-Week Range:
$82.81
$132.60
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
108.62 | 22.02B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-26 | Initiated | Canaccord Genuity | Buy |
| Jun-22-26 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-22-26 | Initiated | Bernstein | Mkt Perform |
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Feb-05-26 | Initiated | H.C. Wainwright | Buy |
| Jan-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-08-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Incyte plans to publish third-quarter results at 7 a.m. Oct. 29, then hold a call at 8. - Stock Titan
Incyte Corporation (INCY) Stock Forecasts - Yahoo Finance
Incyte Corp. Stock Grades | INCY - Barron's
Form 4 Incyte Corporation For: 2 October By Investing.com - Investing.com Canada
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - The Globe and Mail
INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research
A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan
Incyte will present research on eczema, vitiligo and painful skin conditions in Vienna - Stock Titan
More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan
Incyte Genomics Inc (INCY) Revenue 2025: $5.1B, up 21.2% - Stock Titan
Incyte Genomics Inc (INCY) Total Assets 2025: $7.0B, up 27.8% - Stock Titan
Incyte Genomics Inc (INCY) EPS 2025: $6.41, up 4173.3% - Stock Titan
Incyte Genomics Inc (INCY) Net Income 2025: $1.3B, up 3846.9% - Stock Titan
Incyte (INCY): 3 Reasons We Love This Stock - Yahoo Finance
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today - Benzinga
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference - Investing.com
Profitable Biotech Incyte Stock Forms Handle Amid Strong Institutional Accumulation - Investor's Business Daily
Cantor Fitzgerald reiterates Neutral on Incyte stock after conference By Investing.com - Investing.com South Africa
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte at Cantor conference: pipeline advances, post-Jakafi plan - investing.com
Incyte Announces Funding of MINJUVI® (tafasitamab) for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program - Yahoo Finance
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com India
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - investing.com
Incyte at Wells Fargo healthcare conference: pipeline aims to reshape growth - Investing.com UK
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup - ChartMill
Incyte Corp. (INCY) Peer Comparison – Compare with Others - Value Research
Incyte Corp. (INCY) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Incyte (INCY) Institutional Ownership 2026 $INCY - MarketBeat
Incyte Corp. (INCY) Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off - The Globe and Mail
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal - Investing.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
BMO reiterates Incyte stock rating on CMS pricing agreement - Investing.com
Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Acce - GuruFocus
Incyte agrees CMS pricing deal for Jakafi, avoids certain future mandates; no change to 2026 guidance - TradingView
Incyte (NASDAQ: INCY) expects to sidestep new CMS drug pricing rules - Stock Titan
Incyte Corporation Enters Agreement with U.S. Centers for Medicare & Medicaid Services - marketscreener.com
Josh Brown Says ‘Take a Break From AI CapEx World,’ Highlights His 2 Top Healthcare Stock Picks - Yahoo Finance
Incyte (INCY) Nears New ESMO Data For KRAS G12D Candidate 734 - Yahoo Finance
Incyte Stock Price Forecast. Should You Buy INCY? - StockInvest.us
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte stock price target maintained at $150 by H.C. Wainwright - Investing.com
Incyte (INCY) Up 0.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Incyte Corp Stock (INCY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PABLO CAGNONI | Officer |
Sep 15 '26 |
Proposed Sale |
120.49 |
23,218 |
2,797,571 |
0 |
| CAGNONI PABLO J | President, Global Head of R&D |
Sep 15 '26 |
Sale |
120.49 |
23,218 |
2,797,629 |
183,200 |
| CAGNONI PABLO J | President, Global Head of R&D |
Aug 19 '26 |
Sale |
125.56 |
10,801 |
1,356,174 |
183,200 |
| PABLO CAGNONI | Officer |
Aug 19 '26 |
Proposed Sale |
125.56 |
10,801 |
1,356,190 |
0 |
| CAGNONI PABLO J | President, Global Head of R&D |
Aug 12 '26 |
Sale |
120.04 |
10,803 |
1,296,792 |
194,001 |
| PABLO CAGNONI | Officer |
Aug 12 '26 |
Proposed Sale |
120.04 |
10,803 |
1,296,774 |
0 |
| Mayes Patrick A | EVP & Chief Scientific Officer |
Aug 05 '26 |
Option Exercise |
106.47 |
2,207 |
234,979 |
63,648 |
| CAGNONI PABLO J | President, Global Head of R&D |
Aug 05 '26 |
Sale |
122.69 |
10,640 |
1,305,422 |
204,804 |
| Mayes Patrick A | EVP & Chief Scientific Officer |
Aug 05 '26 |
Sale |
123.99 |
2,207 |
273,646 |
61,441 |
| PABLO CAGNONI | Officer |
Aug 05 '26 |
Proposed Sale |
122.69 |
10,640 |
1,305,450 |
0 |
7.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):